Annuncio • Sep 07
RLS Global AB (publ) Announces First Patient Included in New Clinical Investigation on Pressure Ulcers RLS Global AB's new clinical investigation with ChloraSolv for the treatment of pressure ulcers includes six clinics in Sweden, Finland and the UK. The first patient was enrolled on September 1 at a clinic in the UK. The investigation has been approved by authorities in all three countries. Pressure ulcers belong to the group of hard-to-heal wounds and cause much suffering and high costs worldwide. Studies show that pressure ulcers affect as many as over 10 (6-27)% of all hospitalised patients in Europe (ref). Previous investigations have shown that ChloraSolv is effective and safe in the treatment of hard-to- heal leg ulcers and diabetic foot ulcers in need of debridement. This investigation is being carried out to extend the use of ChloraSolv and thus the opportunity to help even more patients. ChloraSolv is a debriding gel, based on a unique hypochlorite technology, which is used with very good effect on leg ulcers and diabetic foot Ulcers. The gel allows the gentle removal of devitalised tissue and promotes natural wound healing. ChloraSolv does not damage healthy tissue and is well tolerated by the patient. Board Change • Sep 06
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Karin Eliasson was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 27
Second quarter 2023 earnings released Second quarter 2023 results: Net loss: kr7.54m (loss widened 29% from 2Q 2022). Revenue is forecast to grow 102% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Annuncio • Aug 23
RLS Global AB (publ) Announces Chief Financial Officer Changes RLS Global AB (publ) announced that Torbjörn Sannerstedt has been appointed new Chief Financial Officer (CFO). Torbjörn succeeds RLS Global's outgoing CFO, Eva Jagenheim. Torbjörn Sannerstedt holds an MBA and has extensive experience from positions as CFO in companies such asAcadeMedia AB, Navamedic ASA and Halmstad Energi och Miljö AB. He has also been CEO of LMI Selcom AB andadministrative manager of Kinnasand AB. Torbjörn Sannerstedt will perform his assignment for RLS Global on aconsultancy basis through the company Business Control Partner Norden AB in Göteborg. Reported Earnings • Jun 01
First quarter 2023 earnings released First quarter 2023 results: Net loss: kr7.50m (loss widened 46% from 1Q 2022). Revenue is forecast to grow 93% p.a. on average during the next 3 years, compared to a 29% growth forecast for the Pharmaceuticals industry in Sweden. Reported Earnings • Mar 06
Full year 2022 earnings released: kr0.35 loss per share (vs kr0.17 loss in FY 2021) Full year 2022 results: kr0.35 loss per share (further deteriorated from kr0.17 loss in FY 2021). Net loss: kr24.4m (loss widened 117% from FY 2021). Revenue is forecast to grow 80% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Annuncio • Jan 25
Steve Krognes to Step Down as Chairman RLS Global AB announced that Lars Johansson is nominated for election as new Chairman of the Board. Current Chairman Steve Krognes will step down and the change of Chairman is planned for an upcoming extraordinary general shareholder meeting. Lars Johansson is an experienced Managing Director and board professional from the medical device and pharmaceutical industries. He brings significant leadership experience both from Sweden and internationally, and has worked at Johnson & Johnson for close to three decades in positions of increasing seniority and impact. His most recent previous experience includes CEO Nordics at Janssen-Cilag and CEO Nordics at Johnson & Johnson where he had leadership responsibility for several hundreds of people and several hundred million dollars of annual revenues. Lars brings a wealth of commercial experience and proven leadership skills. He is currently serving on the boards of Schain Research AB and ProstaLund AB. Steve Krognes has served on the Board of RLS Global since 2018 and as Chairman since 2021. The appointment of Lars Johansson as Chairman of the Board is planned for an extra general meeting on February 9, 2023. A formal notice will follow shortly. Lars Johansson is proposed to be elected as Chairman with immediate effect. Reported Earnings • Nov 25
Third quarter 2022 earnings released Third quarter 2022 results: Net loss: kr5.20m (loss narrowed 16% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 26
Second quarter 2022 earnings released Second quarter 2022 results: Net loss: kr5.84m (down 169% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Annuncio • Aug 23
RLS Global AB (publ) Announces Appointment of Björn Larsson as CEO, Effective October 1, 2022 RLS Global AB (publ) announced that the Board of Directors of Company has appointed Björn Larsson as new CEO. Björn Larsson, who joins the company from Observe Medical ASA, will assume the role of CEO on 1 October. Björn Larsson has solid experience from the global medical device and pharmaceutical industry where he has held various positions in companies such as ABIGO Medical AB and AstraZeneca. Annuncio • Jun 01
RLS Global AB (publ) Introduces Chlorasolv in the Veterinary Care Segment in Scandinavia RLS Global's strategic focus is to expand its technical platform, buffered hypochlorite technology, to new indications, applications and geographical areas. RLS Global can announced a strategic partnership with Swevet in the animal care segment for Sweden, Norway and Denmark. During the second half of 2022, RLS Global will review the alternatives to establish distribution networks for the animal care segment in the rest of Europe and the Middle East. RLS Global has established relationships with animal hospitals within the large international animal care groups Anicura and Evidensia, clinics that are now ready to start using ChloraSolv in their treatments of hard to heal wounds. Together with veterinarians, RLS Global has evaluated ChloraSolv in the treatment of hard to heal wounds in dogs, cats and horses. As the results are very positive, RLS Global is now establishing a Scandinavian distribution network through an exclusivity agreement with Swevet. Swevet is Sweden's only full-range wholesaler when it comes to animal health and works closely with veterinarians and other staff at animal care clinics to support them in their business with knowledge and products. Hard to heal wounds are a reality in animal health, as well as in the human care. Wounds can be caused by everything from shards of glass and other sharp objects, to fights and bites and are also linked to diabetes. Healing can be made more difficult by bacteria and dirt from the outside or the animal licking the wound. Reported Earnings • May 12
First quarter 2022 earnings released: kr0.077 loss per share (vs kr0.094 loss in 1Q 2021) First quarter 2022 results: kr0.077 loss per share (up from kr0.094 loss in 1Q 2021). Net loss: kr5.16m (loss narrowed 18% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Annuncio • Apr 04
RLS Global AB (publ) Announces Resignation of Karin Fischer as CEO Karin Fischer has given notice that she intends to resign as CEO of RLS Global AB (publ). The Board has initiated the search for a new, R&D-focused CEO and Karin Fischer will continue in her role, until a new CEO has been appointed, to ensure a smooth succession. RLS Global ("RLS") has over the past few years, under Karin Fischer's leadership, transformed into a commercial stage wound care company. The expansion in Europe is well underway through partnership with ConvaTec, which is responsible for the commercialization of ChloraSolv in these markets. European regulatory approval for ChloraSolv, the company's main product for debridement of hard-to-heal wounds, has been secured and the product is launched in certain European countries. As previously communicated, RLS' strategic focus is on expanding ChloraSolv into new indications and therapeutic areas, such as burns, pressure ulcers and animal care, through clinical trials generating further clinical evidence. The focus is also on expanding into new geographies through the partnership with ConvaTec and/or with other leading companies. Reported Earnings • Feb 27
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: kr0.17 loss per share (up from kr0.34 loss in FY 2020). Net loss: kr11.2m (loss narrowed 50% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 14
Third quarter 2021 earnings released Third quarter 2021 results: Net loss: kr6.21m (loss widened 12% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Board Change • Sep 14
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Member of the Board Karin Eliasson was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Sep 13
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Member of the Board Karin Eliasson was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Sep 08
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Member of the Board Karin Eliasson was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Sep 07
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Member of the Board Karin Eliasson was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Sep 06
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Member of the Board Karin Eliasson was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 18
Second quarter 2021 earnings released: EPS kr0.13 (vs kr0.085 loss in 2Q 2020) Second quarter 2021 results: Net income: kr8.51m (up kr14.2m from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Jun 23
CEO & Chairman of the Management Board recently bought kr101k worth of stock On the 18th of June, Karin Fischer bought around 14k shares on-market at roughly kr7.47 per share. This was the largest purchase by an insider in the last 3 months. Karin has been a buyer over the last 12 months, purchasing a net total of kr232k worth in shares. Annuncio • Jun 15
RLS Global AB (publ) Announces Outcome of the Complete Clinical Study ChloraSolv01 RLS Global AB (publ) announced that the outcome of the completed clinical study ChloSolv01 is published on June 14, 2021 in t the Journal of Wound Care Vol 30, No 6, June 2021. Data from this clinical study show that a treatment regimen based on ChloraSolv could represent a valuable treatment option for patients suffering from hard-to-heal wounds. The wounds that were treated in the ChloraSolv01 clinical study were hard-to-heal, lower extremity ulcers which had more than 50% coverage of devitalized tissue. Using ChloraSolv once a week for 5 weeks resulted in a 73% reduction of the devitalized tissue and the reduction of wound size during the study period shows that ChloraSolv does not negatively affect the natural healing process. The treatment was generally well tolerated, and patients reported a low pain score during the treatments. It is also shown that the treatment was perceived as positive and easy to handle both from the perspective of care recipients and caregivers. Annuncio • May 31
RLS Global AB Receives Regulatory Approval for ChloraSolv RLS Global AB has received regulatory approval for ChloraSolv regarding the treatment of diabetic foot ulcers in Kuwait. With this approval, RLS has established the first market presence in the Middle East, which is an important region for RLS. Kuwait is the first step in establishing RLS' presence in the Middle East. RLS has established a partnership with a local distributor active in the medical device business. During the registration process, the distributor has built up an important network of clinics that have interest and need for ChloraSolv, and the commercial launch did start in connection with the approval. In parallel, the RLS distributor will apply for an extended indication for ChloraSolv (leg ulcers) in Kuwait which is expected in about five months. Reported Earnings • May 09
First quarter 2021 earnings released First quarter 2021 results: Net loss: kr6.29m (loss widened 61% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 10% per year, which means it is performing significantly worse than earnings. Annuncio • Mar 21
REGEDENT AG completed the acquisition of PeriSolv from RLS Global AB (publ) (OM:RLS). REGEDENT AG agreed to acquire PeriSolv from RLS Global AB (publ) (OM:RLS) for SEK 4 million on February 24, 2020. The consideration of additional payments would be paid until 2032. In a related transaction, during the year, RLS intention is to find a buyer for CariSolv as well.
REGEDENT AG completed the acquisition of PeriSolv from RLS Global AB (publ) (OM:RLS) on March 20, 2021. Is New 90 Day High Low • Feb 24
New 90-day low: kr5.92 The company is down 8.0% from its price of kr6.44 on 25 November 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period. Reported Earnings • Feb 12
Full year 2020 earnings released: kr0.003 loss per share (vs kr0.44 loss in FY 2019) Full year 2020 results: Net loss: kr224.6k (loss narrowed 99% from FY 2019). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Jan 27
New 90-day high: kr7.40 The company is up 16% from its price of kr6.40 on 28 October 2020. The Swedish market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period. Is New 90 Day High Low • Dec 16
New 90-day low: kr5.96 The company is down 8.0% from its price of kr6.50 on 16 September 2020. The Swedish market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period. Recent Insider Transactions • Nov 19
CEO & Chairman of the Management Board recently bought kr131k worth of stock On the 13th of November, Karin Fischer bought around 20k shares on-market at roughly kr6.57 per share. This was the largest purchase by an insider in the last 3 months. Karin has been a buyer over the last 12 months, purchasing a net total of kr329k worth in shares. Annuncio • Oct 15
RLS Global Presents Positive Results from the Chlorasolv01 Study at the Leading European Wound Management Conference, EWMA 2020 RLS Global announced that an abstract has been reviewed by the EW MA Scientific Committee and accepted for Oral Presentation at the EW MA 2020 Virtual Conference. The abstract presents a few key data from the clinical study ChloraSolv01. The Intention-to-treat (ITT) population consisted of 57 patients with a median age of 73 years. Inclusion criteria was all wounds below the knee. It was found that after only six treatments /debridements (last treatment) with ChloraSolv, 71.4% of the patients had 50% reduction of devitalized tissue. The study showed low pain score in general. The change of devitalized tissue from baseline to post debridement at visit 6 was -72.7%. At the same time, the wound size reduction was -30.9%. An overall evaluation by the investigators/nurses showed that 68,9% of the responders agree that ChloraSolv debridement gel makes the debridement easier than previously used debriding treatments, whereas only 3,8% do not agree. This investigation showed that debridement in conjunction with the use of ChloraSolv was well tolerated and efficient. Most of the investigators/nurses found that debridement was easier performed with ChloraSolv than treatments previously used. Annuncio • Oct 04
RLS Global Announces Acceptance of ChloraSolv by Region Skåne RLS Global announced the acceptance of ChloraSolv by Region Skåne. ChloraSolv is available as of September 29[th]. This is the result of positive clinical evaluations from both acute- and primary care and it is an important milestone for RLS as Region Skåne is one of the large regions in Sweden with about 1,4 million inhabitants. RLS works systematically with the regions on the Swedish market with the aim of getting ChloraSolv on tender agreements. The pandemic impact has made the processes longer, but now the procurement departments are starting to open for a dialogue and decision making. ChloraSolv is awarded on contract in three regions. There is a strong interest in the product, and above all, the primary care sector finds this technology an important complement in the treatment of chronic wounds. In Region Kalmar, the company have repeated orders. In the Stockholm Region, the launch has started and RLS is now educating the care givers about ChloraSolv and the first orders are delivered. Is New 90 Day High Low • Sep 25
New 90-day low: kr6.06 The company is down 15% from its price of kr7.14 on 26 June 2020. The Swedish market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 25% over the same period. Annuncio • Sep 18
RLS Global AB Presents Data About Chlorasolv and its Rapid Response and High Efficacy on Biofilm RLS Global AB announced that it presents data about ChloraSolv and its rapid response and high efficacy on biofilm at the EWMA (European Wound Management Association) Conference in November, RLS will present data where technology has been evaluated in an ex-vivo wound model with results on biofilm. The evaluation was carried out together with RISE, Research Institute of Sweden. Biofilm is challenging in Wound Management. Staphylococcus aureus and Pseudomonas aeruginosa are two common bacteria that form biofilms in chronic wounds. A biofilm is formed by a high number of bacteria that protect themselves through a secretion of a viscous barrier. One consequence of biofilm formation is that the individual’s ability to kill bacteria through their immune system is hindered. Another consequence is that the bacteria is protected from antibiotics and several antiseptics. The purpose of the study was to investigate the effect of ChloraSolv on these two bacteria. The results show that ChloraSolv has a rapid effect on both bacteria. In Staphylococcus aureus biofilm, 33% of the bacteria were killed in 30 seconds and more than 81% in five minutes. The effect on Pseudomonas aeruginosa is more immediate and kills more than 95% after 30 seconds. After five minutes, 97% of the bacteria are gone from the wound model. To follow up on these results, RLS initiated a research program together with scientists from Lund University. The purpose is to investigate ChloraSolv’s effect on new biofilm models. The aim was to investigate biofilm reduction in the treatment of chronic wounds, but also in new clinical areas such as dermatology and burns. The results so far are very promising and will be published in a scientific journal. 
